I agree that this site is using cookies. You can find further informations here.
X
Guigay, Joël
109  results:
Search for persons X
?
1

Cetuximab versus methotrexate in first-line treatment of ol..:

Guigay, Joël ; Ortholan, Cécile ; Vansteene, Damien...
The Lancet Healthy Longevity.  5 (2024)  3 - p. e182-e193 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Admin..:

Bokemeyer, Carsten ; Ciardiello, Fortunato ; Dubreuil, Olivier...
Future Oncology.  20 (2024)  7 - p. 393-407 , 2024
Link: https://doi.org/10.2217/..
 
?
3

Adapted EXTREME regimen in the first-line treatment of fit,..:

Guigay, Joël ; Le Caer, Hervé ; Ferrand, François-Régis...
The Lancet Healthy Longevity.  5 (2024)  6 - p. e392-e405 , 2024
Link: https://doi.org/10.1016/..
 
?
4

NISCAHN: a phase II trial of nivolumab in patients with sal..:

Fayette, Jérôme ; Even, Caroline ; Digue, Laurence...
BMJ Oncology.  2 (2023)  1 - p. e000065 , 2023
Link: https://doi.org/10.1136/..
 
?
5

Long-term Outcomes with Nivolumab as First-line Treatment i..:

Gillison, Maura L ; Blumenschein Jr, George ; Fayette, Jerome...
The Oncologist.  27 (2022)  2 - p. e194-e198 , 2022
Link: https://doi.org/10.1093/..
 
?
6

A phase II study of monalizumab in patients with recurrent/..:

Galot, Rachel ; Le Tourneau, Christophe ; Saada-Bouzid, Esma...
European Journal of Cancer.  158 (2021)  - p. 17-26 , 2021
Link: https://doi.org/10.1016/..
 
?
7

Efficacy and safety of immune checkpoint inhibitors in elde..:

Saleh, Khalil ; Auperin, Anne ; Martin, Nicolas...
European Journal of Cancer.  157 (2021)  - p. 190-197 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Phase I trial of copanlisib, a selective PI3K inhibitor, in..:

Marret, Grégoire ; Isambert, Nicolas ; Rezai, Keyvan...
Investigational New Drugs.  39 (2021)  6 - p. 1641-1648 , 2021
Link: https://doi.org/10.1007/..
 
?
9

Observational, prospective, phase 4 study in patients with ..:

Guigay, Joël ; Chamorey, Emmanuel ; Lefebvre, Gautier...
Cancer Reports.  5 (2021)  2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

Avelumab for platinum-ineligible/refractory recurrent and/o..:

Guigay, Joël ; Lee, Keun-Wook ; Patel, Manish R...
Journal for ImmunoTherapy of Cancer.  9 (2021)  10 - p. e002998 , 2021
Link: https://doi.org/10.1136/..
 
?
11

Hyperprogression under Immune Checkpoint Inhibitor: a poten..:

Refae, Sadal ; Gal, Jocelyn ; Brest, Patrick...
Scientific Reports.  10 (2020)  1 - p. , 2020
Link: https://doi.org/10.1038/..
 
?
12

Author Correction: Hyperprogression under Immune Checkpoint..:

Refae, Sadal ; Gal, Jocelyn ; Brest, Patrick...
Scientific Reports.  10 (2020)  1 - p. , 2020
Link: https://doi.org/10.1038/..
 
?
13

Avelumab–cetuximab–radiotherapy versus standards of care in..:

Tao, Yungan ; Aupérin, Anne ; Sun, Xushan...
European Journal of Cancer.  141 (2020)  - p. 21-29 , 2020
Link: https://doi.org/10.1016/..
 
?
14

The OncoAge Consortium: Linking Aging and Oncology from Ben..:

Hofman, Paul ; Ayache, Nicholas ; Barbry, Pascal...
Cancers.  11 (2019)  2 - p. 250 , 2019
Link: https://doi.org/10.3390/..
 
?
15

Cetuximab pharmacokinetic/pharmacodynamics relationships in..:

Le Louedec, Félicien ; Alix‐Panabières, Catherine ; Lafont, Thierry...
British Journal of Clinical Pharmacology.  85 (2019)  6 - p. 1357-1366 , 2019
Link: https://doi.org/10.1111/..
 
1-15